|
US4350687A
(en)
|
1980-02-10 |
1982-09-21 |
Research Corporation |
Platelet derived cell growth factor
|
|
JPS60146833A
(ja)
|
1984-01-10 |
1985-08-02 |
Green Cross Corp:The |
モノクロ−ナル抗体製剤
|
|
JPS6178731A
(ja)
|
1985-05-20 |
1986-04-22 |
Green Cross Corp:The |
加熱処理免疫グロブリン製剤
|
|
CA1327161C
(en)
|
1987-09-01 |
1994-02-22 |
Mitsugu Kobayashi |
Lyophilized pharmaceutical composition of neocarzinostatin derivative
|
|
SE8801537D0
(sv)
|
1988-04-26 |
1988-04-26 |
Ellco Food Ab |
Cellodlingsmedium samt forfarande for dess framstellning
|
|
US5252713A
(en)
|
1988-09-23 |
1993-10-12 |
Neorx Corporation |
Polymeric carriers for non-covalent drug conjugation
|
|
CA2049342A1
(en)
|
1989-03-27 |
1990-09-28 |
Sally Bolmer |
Formulations for stabilizing of igm antibodies
|
|
US5116944A
(en)
|
1989-12-29 |
1992-05-26 |
Neorx Corporation |
Conjugates having improved characteristics for in vivo administration
|
|
US5216130A
(en)
|
1990-05-17 |
1993-06-01 |
Albany Medical College |
Complex for in-vivo target localization
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5260308A
(en)
|
1991-11-06 |
1993-11-09 |
Mayo Foundation For Medical Education And Research |
Method to increase permeability of the blood-nerve/brain barriers to proteins
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
WO1999000113A1
(en)
|
1997-06-27 |
1999-01-07 |
Vivorx Pharmaceuticals, Inc. |
Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
|
PT910382E
(pt)
|
1996-04-26 |
2003-10-31 |
Genaera Corp |
Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
|
|
GB9613182D0
(en)
|
1996-06-24 |
1996-08-28 |
Nycomed Imaging As |
Method
|
|
US6416967B2
(en)
|
1996-07-12 |
2002-07-09 |
Precision Therapeutics, Inc. |
Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
|
|
US5728541A
(en)
|
1996-07-12 |
1998-03-17 |
Precision Therapeutics, Inc. |
Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
|
|
US8853260B2
(en)
|
1997-06-27 |
2014-10-07 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
US7041301B1
(en)
|
1997-11-07 |
2006-05-09 |
Mayo Foundation For Medical Education And Research |
Interferon immunotherapy
|
|
US6616925B1
(en)
|
1998-04-02 |
2003-09-09 |
I.D.M. Immuno-Designed Molecules |
Combined preparation for the treatment of neoplasic diseases or of infectious diseases
|
|
US7112409B2
(en)
|
1999-01-29 |
2006-09-26 |
Center For Molecular Medicine And Immunology |
Method of determining cytokine dosage for myelosuppressive state
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US6420378B1
(en)
|
1999-10-15 |
2002-07-16 |
Supergen, Inc. |
Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
|
|
DE10132502A1
(de)
|
2001-07-05 |
2003-01-23 |
Gsf Forschungszentrum Umwelt |
Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
|
|
NZ536420A
(en)
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
|
WO2004004661A2
(en)
|
2002-07-09 |
2004-01-15 |
Point Therapeutics, Inc. |
Boroproline compound combination therapy
|
|
JP4596916B2
(ja)
|
2002-09-05 |
2010-12-15 |
メディミューン，エルエルシー |
Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
|
|
US8034334B2
(en)
|
2002-09-06 |
2011-10-11 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
|
|
DK1585548T3
(en)
|
2002-12-09 |
2018-09-03 |
Abraxis Bioscience Llc |
COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
EP1675465B1
(en)
|
2003-10-22 |
2010-03-03 |
The Johns Hopkins University |
Improved combination bacteriolytic therapy for the treatment of tumors
|
|
AU2005240020B2
(en)
|
2004-04-22 |
2011-02-10 |
Eli Lilly And Company |
Composition comprising a Survivin oligonucleotide and gemcitabine for the treatment of cancer
|
|
ES2529660T3
(es)
*
|
2004-05-14 |
2015-02-24 |
Abraxis Bioscience, Llc |
Métodos de tratamiento en los que se utilizan las proteínas de unión a albúmina como dianas
|
|
CA2577133A1
(en)
*
|
2004-08-19 |
2006-03-23 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
WO2006034455A2
(en)
|
2004-09-23 |
2006-03-30 |
Vasgene Therapeutics, Inc. |
Polipeptide compounds for inhibiting angiogenesis and tumor growth
|
|
CA2583389A1
(en)
|
2004-10-07 |
2006-04-20 |
Emory University |
Multifunctional nanoparticles conjugates and their use
|
|
US8735394B2
(en)
*
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
US20070166388A1
(en)
|
2005-02-18 |
2007-07-19 |
Desai Neil P |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
CN103169729A
(zh)
|
2005-02-18 |
2013-06-26 |
阿布拉科斯生物科学有限公司 |
治疗剂的组合和给予方式以及联合治疗
|
|
CN101355928B
(zh)
|
2005-04-26 |
2013-05-22 |
卫材R&D管理株式会社 |
用于癌症免疫疗法的组合物和方法
|
|
US10183076B2
(en)
|
2005-05-16 |
2019-01-22 |
Resdevco Research And Development Co. L |
Topical compositions for treatment of irritation of mucous membranes
|
|
US7771751B2
(en)
|
2005-08-31 |
2010-08-10 |
Abraxis Bioscience, Llc |
Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
|
|
CN101291658B
(zh)
|
2005-08-31 |
2014-04-16 |
阿布拉科斯生物科学有限公司 |
用于制备稳定性增加的水难溶性药物的组合物和方法
|
|
US7776832B2
(en)
|
2006-04-21 |
2010-08-17 |
Gem Pharmaceuticals, Llc |
Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
|
|
PL2081595T3
(pl)
|
2006-09-26 |
2019-11-29 |
Genmab As |
Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
|
|
US20100173794A1
(en)
|
2006-10-17 |
2010-07-08 |
Koninklijke Philips Electronics N.V. |
Device for amplification and detection of nucleic acids
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
|
US20100112077A1
(en)
*
|
2006-11-06 |
2010-05-06 |
Abraxis Bioscience, Llc |
Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
|
|
AU2007317858A1
(en)
*
|
2006-11-07 |
2008-05-15 |
Dow Agrosciences Llc |
Sprayable, controlled-release, male annihilation technique (MAT) formulation and insect control method
|
|
EP2104501B1
(en)
|
2006-12-13 |
2014-03-12 |
Merck Sharp & Dohme Corp. |
Methods of cancer treatment with igf1r inhibitors
|
|
EP3417859A1
(en)
|
2007-03-07 |
2018-12-26 |
Abraxis BioScience, LLC |
Nanoparticle comprising rapamycin and albumin as anticancer agent
|
|
AU2008224929A1
(en)
|
2007-03-14 |
2008-09-18 |
Mayo Foundation For Medical Education And Research |
Treating skin cancer
|
|
US20110014117A1
(en)
|
2007-06-28 |
2011-01-20 |
Schering Corporation |
Anti-igf1r
|
|
CA2700457A1
(en)
|
2007-10-01 |
2009-04-09 |
Austin Smith |
Neural tumor stem cells and methods of use thereof
|
|
RU2010120674A
(ru)
|
2007-10-22 |
2011-11-27 |
Шеринг Корпорейшн (US) |
Полностью человеческие анти-vegf-антитела и способы их применения
|
|
WO2009060198A1
(en)
|
2007-11-09 |
2009-05-14 |
Peregrine Pharmaceuticals, Inc. |
Anti-vegf antibody compositions and methods
|
|
EP3266453A1
(en)
|
2008-07-03 |
2018-01-10 |
Mayo Foundation for Medical Education and Research |
Treating cancer
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
WO2010017216A2
(en)
|
2008-08-04 |
2010-02-11 |
Allocure |
Mesenchymal stromal cell populations and methods of isolating and using same
|
|
WO2010075540A1
(en)
|
2008-12-23 |
2010-07-01 |
Burnham Institute For Medical Research |
Methods and compositions for synaphically-targeted treatment for cancer
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
CA2757645C
(en)
|
2009-04-06 |
2018-05-15 |
Mayo Foundation For Medical Education And Research |
Methods and materials for delivering molecules
|
|
MX2011010673A
(es)
|
2009-04-10 |
2012-02-21 |
Abraxis Bioscience Llc |
Formulaciones de nanoparticulas y usos de las mismas.
|
|
US8571805B2
(en)
|
2009-04-10 |
2013-10-29 |
Pharmaco-Kinesis Corporation |
Method and apparatus for detecting and regulating vascular endothelial growth factor (VEGF) by forming a homeostatic loop employing a half-antibody biosensor
|
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
EA201190273A1
(ru)
|
2009-05-28 |
2012-12-28 |
Глаксо Груп Лимитед |
Комбинация антагониста tnf-альфа и антагониста vegf для применения в лечении или предупреждении заболеваний глаз
|
|
US8345535B2
(en)
*
|
2009-07-13 |
2013-01-01 |
Lg Electronics Inc. |
Method and apparatus for generating ranging preamble code in wireless communication system
|
|
AR078161A1
(es)
*
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
CA2780130A1
(en)
|
2009-11-05 |
2011-05-12 |
The Uab Research Foundation |
Treating basal-like genotype cancers
|
|
JP2013510804A
(ja)
|
2009-11-13 |
2013-03-28 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
化学療法剤を装荷したナノ粒子に結合した抗インテグリン抗体
|
|
EP2504032A4
(en)
*
|
2009-11-24 |
2013-06-19 |
Alderbio Holdings Llc |
IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
|
|
AR080154A1
(es)
*
|
2010-02-10 |
2012-03-14 |
Immunogen Inc |
Anticuerpos cd20 y su utilizacion
|
|
CA2801891C
(en)
|
2010-06-07 |
2020-10-27 |
Abraxis Bioscience, Llc |
Combination therapy methods for treating proliferative diseases
|
|
US9466148B2
(en)
|
2010-09-03 |
2016-10-11 |
Disney Enterprises, Inc. |
Systems and methods to dynamically adjust an image on a display monitor represented in a video feed
|
|
US20130281376A1
(en)
*
|
2010-10-08 |
2013-10-24 |
Abraxis Bioscience, Llc |
Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer
|
|
US8992908B2
(en)
*
|
2010-11-23 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of oral mucositis
|
|
US20130281377A1
(en)
|
2010-12-23 |
2013-10-24 |
Mayo Foundation For Medical Education And Research |
Treating multiple myeloma
|
|
HUE048876T2
(hu)
|
2011-05-09 |
2020-08-28 |
Mayo Found Medical Education & Res |
Rákos megbetegedések kezelése
|
|
US20130028895A1
(en)
|
2011-07-27 |
2013-01-31 |
Gerald Wulf |
Exosome inhibiting agents and uses thereof
|
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
WO2013071058A1
(en)
|
2011-11-09 |
2013-05-16 |
The Uab Research Foundation |
Her3 antibodies and uses thereof
|
|
US11471486B2
(en)
|
2012-09-04 |
2022-10-18 |
Inven2 As |
Selective and controlled expansion of educated NK cells
|
|
US10413606B2
(en)
|
2012-10-01 |
2019-09-17 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
|
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
|
US20140186447A1
(en)
|
2012-12-28 |
2014-07-03 |
Abraxis Bioscience, Llc |
Nanoparticle compositions of albumin and paclitaxel
|
|
DK3049441T3
(da)
|
2013-09-27 |
2020-02-03 |
Hoffmann La Roche |
Anti-PDL1-antistofformuleringer
|
|
EP3154586B1
(en)
*
|
2014-06-13 |
2020-05-27 |
Mayo Foundation for Medical Education and Research |
Treating lymphomas
|
|
US10213513B2
(en)
|
2014-06-16 |
2019-02-26 |
Mayo Foundation For Medical Education And Research |
Treating myelomas
|
|
CN107073132B
(zh)
|
2014-10-06 |
2021-08-27 |
梅约医学教育与研究基金会 |
载体-抗体组合物及其制备和使用方法
|
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
|
CA2968680A1
(en)
|
2014-12-02 |
2016-06-09 |
Celgene Corporation |
Combination therapies
|
|
WO2017176265A1
(en)
|
2016-04-06 |
2017-10-12 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
JP6921802B2
(ja)
|
2015-08-18 |
2021-08-18 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ |
キャリア結合剤組成物およびそれを作製および使用する方法
|
|
TW201707725A
(zh)
|
2015-08-18 |
2017-03-01 |
美國馬友醫藥教育研究基金會 |
載體－抗體組合物及其製造及使用方法
|
|
TW201713360A
(en)
|
2015-10-06 |
2017-04-16 |
Mayo Foundation |
Methods of treating cancer using compositions of antibodies and carrier proteins
|
|
WO2017120501A1
(en)
|
2016-01-07 |
2017-07-13 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer with interferon
|
|
US11351254B2
(en)
|
2016-02-12 |
2022-06-07 |
Mayo Foundation For Medical Education And Research |
Hematologic cancer treatments
|
|
WO2017165440A1
(en)
|
2016-03-21 |
2017-09-28 |
Mayo Foundation For Medical Education And Research |
Methods for reducing toxicity of a chemotherapeutic drug
|
|
EP3432928A4
(en)
|
2016-03-21 |
2019-11-20 |
Mayo Foundation for Medical Education and Research |
PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
|
|
US10618969B2
(en)
|
2016-04-06 |
2020-04-14 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
KR102482503B1
(ko)
|
2016-08-05 |
2022-12-30 |
메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 |
암 치료를 위한 변형된 항체-알부민 나노입자 복합체
|
|
CN109890419A
(zh)
|
2016-09-01 |
2019-06-14 |
梅约医学教育与研究基金会 |
用于治疗癌症的载体-pd-l1结合剂组合物
|
|
CN109843336A
(zh)
|
2016-09-01 |
2019-06-04 |
梅约医学教育与研究基金会 |
用于靶向t细胞癌症的方法和组合物
|
|
CN109843924A
(zh)
|
2016-09-06 |
2019-06-04 |
梅约医学教育与研究基金会 |
治疗表达pd-l1的癌症的方法
|
|
US11590098B2
(en)
|
2016-09-06 |
2023-02-28 |
Mayo Foundation For Medical Education And Research |
Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
|
|
AU2017324947A1
(en)
|
2016-09-06 |
2019-03-28 |
Mayo Foundation For Medical Education And Research |
Paclitaxel-albumin-binding agent compositions and methods for using and making the same
|
|
EP3533870A4
(en)
|
2016-10-28 |
2020-04-08 |
NRL Pharma, Inc. |
LACTOFERRIN / ALBUMIN FUSION PROTEIN AND PROCESS FOR PRODUCING THE SAME
|